Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New One-Pill flu treatment for kids shows promise in Late-Stage trial

NCT ID NCT06507813

Disease control Sponsor: Jiaxing AnDiCon Biotech Co.,Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a new flu medicine called ADC189 in 190 children aged 2 to 11 with influenza. The medicine is given as a single dose, either as a tablet or granules. The goal was to see if it is safe and works well in younger children, who currently have limited treatment options. The trial compared ADC189 to an existing drug and placebos.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ADC189 tablets/granules
What this could lead to
If successful, this could offer a convenient single-dose flu treatment for children as young as 2, filling a gap for younger kids.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. The drug may not prove safer or more effective than existing options, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

190 people

The number who actually took part.

Started

Aug 2024

Finished

Apr 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

2 to 11 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * 1\. Patients aged 2 to 11 years at screening, both sex; * 2\. Patients were diagnosed with Influenza A Vairus Infection/Influenza B Virus Infection. * 3\. Parents willing and able to comply with study requirements, under the judgment of investigators . * 4\. Onset of symptoms no more than 48 hours before presentation for screening. Key Exclusion Criteria: * 1\. Patients with severe influenza. * 2\. Pregnant or breast-feeding females * 3\. Patients with acute respiratory infection, tympanitis, sinusitis, or acute asthma attack within 2 weeks before screening. * 4\. Presence of a chronic disease or illness that may indicate increased risk for influenza-related complications. * 5\. Other antiviral therapy is required during screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Influenza A virus infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

influenza swine influenza

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Influenza type A Influenza type B

Contacts and locations

Locations

  • Beijing Children's Hospital,Capital Medical University

    Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.